Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 21 2017 - 4:30PM
Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD)
(NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T
cell therapies, today announced that Patrick Jeanmart, Chief
Financial Officer and David Gilham, VP Research and Development of
Celyad will present a corporate update at the upcoming 29th Annual
Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017
at 4:30 p.m. ET in New York, NY.
A live audio webcast of the presentation will be
available on the Investor Relations section of Celyad’s website
at www.celyad.com/en/investors, where it will be archived for
approximately 90 days.
About Celyad
Celyad is a clinical-stage biopharmaceutical
company focused on the development of specialized CAR-T cell based
therapies. Celyad utilizes its expertise in cell engineering to
target cancer. Celyad’s Natural Killer Receptor based T-Cell
(NKR-T) platform has the potential to treat a broad range of solid
and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T
NKG2D), has been evaluated in a single dose escalation Phase I
clinical trial to assess the safety and clinical activity of
multiple administrations of autologous CYAD-01 cells in seven
refractory cancers including five solid tumors (colorectal,
ovarian, bladder, triple-negative breast and pancreatic cancers)
and two hematological tumors (acute myeloid leukemia and multiple
myeloma). Celyad was founded in 2007 and is based in
Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s
ordinary shares are listed on the Euronext Brussels and Euronext
Paris exchanges, and its American Depository Shares are listed on
the NASDAQ Global Market, all under the ticker symbol CYAD.
For more information about Celyad, please visit:
www.celyad.com
For more information, please
contact:
For Europe: Consilium Strategic Communications
Chris Gardner and Chris Welsh
- T: +44 (0)20 3709 5700 –
celyad@consilium-comms.com |
For France: NewCapPierre
Laurent and Nicolas Mérigeau - T: +
33(0)1 44 71 94 94 - celyad@newcap.eu |
For Belgium: ComfiGunther De
Backer and Sabine Leclercq - T.: +32 (0)2
290 90 90 – celyad@comfi.be |
For the U.S.: Stern Investor RelationsWill
O’Connor and Michael Schaffzin – T.: +1
212.362.1200 – celyad@sternir.com |
To subscribe to Celyad’s newsletter,
visit www.celyad.comFollow us on LinkedIn &
Twitter @CelyadSA
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Sep 2023 to Sep 2024